LCMS
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o. All rights reserved. Content available under a CC BY-SA 4.0 Attribution-ShareAlike

End-to-End Workflow Solutions for Oligonucleotide Analysis

Guides | 2023 | Agilent TechnologiesInstrumentation
Software, HPLC, LC/TOF, LC/HRMS, LC/MS, LC/SQ
Industries
Pharma & Biopharma
Manufacturer
Agilent Technologies

Summary

Importance of the Topic


Synthetic oligonucleotides have become integral tools in biotechnology, diagnostics, and gene therapy, driving demand for reliable analytical workflows that ensure accuracy, purity, and structural integrity of these biomolecules.

Objectives and Study Overview


This guide outlines end-to-end workflows for oligonucleotide analysis, covering four key areas:
  • Purity assessment by LC/UV and LC/MS
  • Characterization of product-related impurities (Target Plus Impurities analysis)
  • Sequence confirmation via LC/MS/MS fragment analysis
  • Scale-up purification from analytical to preparative formats

Methodology and Instrumentation


Workflows employ robust sample preparation using purification cartridges and well-plate formats, followed by chromatographic separation via ion-exchange or ion-pair reversed-phase methods. Detection is performed with UV detectors, single-quadrupole LC/MSD XT, and high-resolution TOF or Q-TOF systems. Data analysis is automated in Agilent MassHunter BioConfirm and OpenLab platforms.

Key Results and Discussion


  • Workflow 1 achieved baseline separation of full-length oligonucleotides and common truncation products for rapid purity profiling
  • Workflow 2 combined high-resolution MS detection with automated feature finding to identify low-abundance impurities such as phosphodiester conversion and abasic species
  • Workflow 3 demonstrated MS/MS fragment matching to confirm complete sequences and modification sites with high confidence
  • Workflow 4 provided scalable purification, delivering microgram to gram quantities with optimized recovery and purity across analytical, semi-preparative, and preparative systems

Benefits and Practical Applications


  • Modular, validated workflows accelerate method development and QC in research and manufacturing
  • Automated data analysis reduces manual interpretation, improving throughput and reproducibility
  • High-resolution MS detection supports regulatory requirements and thorough impurity profiling
  • Scalable purification solutions address diverse sample throughput and quantity needs

Future Trends and Potential Applications


Advancements in chromatographic materials, real-time data processing, and AI-driven spectral interpretation are expected to further enhance sensitivity, speed, and automation. Integration with multi-omics platforms and on-demand purification systems will expand applications in personalized medicine and advanced therapeutics.

Conclusion


The presented end-to-end workflows offer comprehensive strategies for precise oligonucleotide analysis, from initial purity and impurity profiling to definitive sequence confirmation and scalable purification. These approaches support both early-stage research and production QC, ensuring high-quality synthetic oligonucleotides for diverse biotechnological applications.

Used Instrumentation


  • Agilent 1290 Infinity II Bio LC System and 1260 Infinity II Bio-Inert Analytical LC
  • Agilent AdvanceBio Oligonucleotide and PLRP-S columns
  • 6230B TOF and 6545XT AdvanceBio LC/Q-TOF mass spectrometers
  • Agilent OpenLab ChemStation and MassHunter BioConfirm software

References


  • Hsiao J, Apffel A, Turner M Optimize anion-exchange separation of oligonucleotides application note 5994-4753EN
  • Schneider S Comparability studies on four LC systems for nucleotide analysis application note 5994-4392EN
  • Pulliere F, Welsby C Identification of starting materials by capillary electrophoresis application note 5994-4239EN
  • Best Practice for nucleic acid thermal stability by Cary 3500 UV-Vis spectrophotometer white paper 5994-4028EN
  • Rye P, Schwarzer C MS1 oligonucleotide characterization using LC/Q-TOF application note 5994-5631EN
  • Li G, Rye P MS/MS sequencing of oligonucleotides by LC/Q-TOF application note 5994-5632EN
  • Rieck F Purification of single-stranded RNA oligonucleotides application note 5994-3514EN
  • Krieger S, Dickhut C Direct analysis of in-process oligonucleotides application note 5991-9490EN
  • Duong P, Bidlingmeyer BA, Zhu A High-resolution reversed-phase separation of oligonucleotides application note 5991-6006EN
  • Liau B mRNA 5 capping analysis by LC/MS application note 5994-3984EN
  • Wong DL, Rye P Integrated workflow for oligonucleotide sequence confirmation application note 5994-5071EN

Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.

Downloadable PDF for viewing
 

Similar PDF

Toggle
End-To-End Workflow Solutions for Therapeutic Peptides
End-To-End Workflow Solutions for Therapeutic Peptides
2025|Agilent Technologies|Brochures and specifications
Therapeutic Peptides Workflow Resource Guide End-To-End Workflow Solutions for Therapeutic Peptides From research discovery to production QA/QC Ensuring Quality in Therapeutic Peptide Development Peptides are short chains of amino acids, which are the "building blocks" of proteins. Some peptide molecules…
Key words
peptide, peptideopenlab, openlabbundle, bundlesoftware, softwareworkflow, workflowadvancebio, advancebiochemstation, chemstationmsd, msdpreparative, preparativeanalysis, analysisagilent, agilentvaya, vayadetect, detectimpurity, impuritypurification
Driving the Field of Oligonucleotide Therapeutics
Image © Agilent Technologies, Inc. 2024 Sponsored by Driving the Field of Oligonucleotide Therapeutics State-of-the-Art Solutions for Oligonucleotide Characterization, Purification, and Manufacturing / Chapter 1: Introduction to Oligonucleotide Therapeutics / Chapter 2: Challenges for Oligonucleotide Synthesis and Production / Chapter…
Key words
labx, labxebook, ebookoligonucleotide, oligonucleotidebio, biooligos, oligosoligo, oligooligonucleotides, oligonucleotidespurification, purificationanalysis, analysisagilent, agilentsynthesis, synthesisimpurities, impuritiespreparative, preparativepurity, puritysynthetic
End-To-End Workflow Solutions for Short Nucleic Acids and mRNA Analysis
End-To-End Workflow Solutions for Short Nucleic Acids and mRNA Analysis
2024|Agilent Technologies|Brochures and specifications
Oligo Workflow Resource Guide End-To-End Workflow Solutions for Short Nucleic Acids and mRNA Analysis From R&D to QC/production Short synthetic oligonucleotides, such as small interfering RNA, antisense oligonucleotides, aptamers, and CRISPR guides have gained much attention and grown rapidly as…
Key words
nucleic, nucleicfragment, fragmentmrna, mrnaprosize, prosizeoligo, oligoanalyzer, analyzerivt, ivtagilent, agilentbiotek, biotekrna, rnatapestation, tapestationmicroplate, microplatescreentape, screentapeworkstation, workstationpublication
Oligonucleotide Characterization by Agilent 1290 Infinity II Bio LC and 6545XT AdvanceBio LC/Q-TOF
Application Note Pharma & Biopharma Oligonucleotides Oligonucleotide Characterization by Agilent 1290 Infinity II Bio LC and 6545XT AdvanceBio LC/Q-TOF Oligonucleotide identity, impurities analysis and sequence determination using BioConfirm 12.0 target plus impurities (TPI) and sequence confirmation workflows Authors Introduction Bian…
Key words
oligonucleotide, oligonucleotideaso, asosequence, sequencetpi, tpicounts, countsacquisition, acquisitionconfirmation, confirmationoligonucleotides, oligonucleotidesworkflow, workflowcharge, chargeimpurities, impuritiesmass, massbioconfirm, bioconfirmagilent, agilentfluoro
Other projects
GCMS
ICPMS
Follow us
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o. All rights reserved. Content available under a CC BY-SA 4.0 Attribution-ShareAlike